+

WO1999011778B1 - Traitement antisense de l'hypertension pulmonaire - Google Patents

Traitement antisense de l'hypertension pulmonaire

Info

Publication number
WO1999011778B1
WO1999011778B1 PCT/GB1998/002584 GB9802584W WO9911778B1 WO 1999011778 B1 WO1999011778 B1 WO 1999011778B1 GB 9802584 W GB9802584 W GB 9802584W WO 9911778 B1 WO9911778 B1 WO 9911778B1
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic composition
inhaler
seq
composition according
oligonucleotide
Prior art date
Application number
PCT/GB1998/002584
Other languages
English (en)
Other versions
WO1999011778A1 (fr
Inventor
Timothy Higenbottam
Keith Mccormack
Adrian Smith
Original Assignee
Univ Sheffield
Timothy Higenbottam
Keith Mccormack
Adrian Smith
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Sheffield, Timothy Higenbottam, Keith Mccormack, Adrian Smith filed Critical Univ Sheffield
Priority to JP2000508789A priority Critical patent/JP2001515011A/ja
Priority to CA002302167A priority patent/CA2302167A1/fr
Priority to EP98940410A priority patent/EP1009822A1/fr
Priority to AU88741/98A priority patent/AU8874198A/en
Publication of WO1999011778A1 publication Critical patent/WO1999011778A1/fr
Publication of WO1999011778B1 publication Critical patent/WO1999011778B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une méthode de traitement de l'hypertension pulmonaire par une thérapie antisens faisant appel à des molécules antisens dérivées de ET-1 administrées dans les poumons comme une impulsion/pointe dans un inhalateur.
PCT/GB1998/002584 1997-09-02 1998-09-02 Traitement antisense de l'hypertension pulmonaire WO1999011778A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2000508789A JP2001515011A (ja) 1997-09-02 1998-09-02 肺高血圧症のアンチセンス治療
CA002302167A CA2302167A1 (fr) 1997-09-02 1998-09-02 Traitement antisense de l'hypertension pulmonaire
EP98940410A EP1009822A1 (fr) 1997-09-02 1998-09-02 Traitement antisense de l'hypertension pulmonaire
AU88741/98A AU8874198A (en) 1997-09-02 1998-09-02 Antisense treatment of pulmonary hypertension

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9718487.3A GB9718487D0 (en) 1997-09-02 1997-09-02 Pulmonary hypertension
GB9718487.3 1997-09-02

Publications (2)

Publication Number Publication Date
WO1999011778A1 WO1999011778A1 (fr) 1999-03-11
WO1999011778B1 true WO1999011778B1 (fr) 1999-04-15

Family

ID=10818333

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1998/002584 WO1999011778A1 (fr) 1997-09-02 1998-09-02 Traitement antisense de l'hypertension pulmonaire

Country Status (6)

Country Link
EP (1) EP1009822A1 (fr)
JP (1) JP2001515011A (fr)
AU (1) AU8874198A (fr)
CA (1) CA2302167A1 (fr)
GB (1) GB9718487D0 (fr)
WO (1) WO1999011778A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999060010A1 (fr) * 1998-05-21 1999-11-25 Isis Pharmaceuticals, Inc. Compositions destinees a l'administration pulmonaire d'acides nucleiques et procedes
JP2002515513A (ja) * 1998-05-21 2002-05-28 アイシス・ファーマシューティカルス・インコーポレーテッド 核酸の肺送達のための組成物および方法
US6087343A (en) * 1998-09-14 2000-07-11 University Of Florida Antisense oligonucleotides targeted to β-1 adrenoceptor and methods of use
PT1163333E (pt) 1999-03-18 2008-02-19 Queen Mary & Westfield College ''inibidores da síntese de endotelina-1''
AU2001289861A1 (en) * 2000-09-19 2002-04-02 Epidauros Biotechnologie Ag Polymorphisms in human genes of cardiovascular regulators and their use in diagnostic and therapeutic applications
WO2016083624A1 (fr) * 2014-11-28 2016-06-02 Silence Therapeutics Gmbh Moyens d'inhibition de l'expression d'edn1

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2279014B (en) * 1993-06-02 1997-07-16 Niall Keaney Device for controlling delivery of respiratory drugs
GB9320978D0 (en) * 1993-10-12 1993-12-01 Higenbottam Timohy W Nitric oxide treatment
US5994315A (en) * 1995-06-07 1999-11-30 East Carolina University Low adenosine agent, composition, kit and method for treatment of airway disease
GB2320900B (en) * 1997-01-07 2000-08-30 Univ Sheffield Inhalers

Also Published As

Publication number Publication date
AU8874198A (en) 1999-03-22
CA2302167A1 (fr) 1999-03-11
JP2001515011A (ja) 2001-09-18
WO1999011778A1 (fr) 1999-03-11
EP1009822A1 (fr) 2000-06-21
GB9718487D0 (en) 1997-11-05

Similar Documents

Publication Publication Date Title
AU745324B2 (en) Therapeutic methods comprising use of a neuregulin
Sato et al. Anticonvulsant action of a non-competitive antagonist of NMDA receptors (MK-801) in the kindling model of epilepsy
Gordon et al. Enhancement of morphine analgesia by the GABAB agonist baclofen
AU727851B2 (en) Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors
Glazner et al. Elevated insulin-like growth factor (IGF) gene expression in sciatic nerves during IGF-supported nerve regeneration
JP2010535508A5 (fr)
WO2003103697A2 (fr) Utilisation de composes ayant une activite gip dans le traitement de troubles associes a une perte anormale de cellules et/ou dans le traitement de l'obesite
AU2527800A (en) Methods to enhance white blood cell count
Francis Pau et al. Hypothalamic site‐dependent effects of neuropeptide Y on gonadotropin‐releasing hormone secretion in rhesus macaques
WO1999011778B1 (fr) Traitement antisense de l'hypertension pulmonaire
WO2000033814A2 (fr) Technique d'apport d'agents au systeme nerveux central
Wilson 3rd et al. Prolactin message in brain and pituitary of adult male rats is identical: PCR cloning and sequencing of hypothalamic prolactin cDNA from intact and hypophysectomized adult male rats
Hanaoka et al. Effect of 4-methylcatechol on sciatic nerve growth factor level and motor nerve conduction velocity in experimental diabetic neuropathic process in rats
WO2005033282A2 (fr) Compositions polyamide et methodes therapeutiques pour traiter un papillomavirus humain
RU2003134949A (ru) Способ лечения деменции и нейродегенеративных заболеваний и применение в нем качестве лекарственного средства промежуточных доз антагонистов lhrh
AU2002310788A1 (en) Treatment of dementia and neurodegenerative diseases with intermediate doses of LHRH antagonists
Hefti et al. Protective effects of nerve growth factor and brain-derived neurotrophic factor on basal forebrain cholinergic neurons in adult rats with partial fimbrial transections
EP1213017A2 (fr) Utilisation d'un agoniste du récepteur 5-HT2C pour traiter les bouffées de chaleur
US9668995B2 (en) Treatment of motor fluctuations
WO2007139433A8 (fr) Substance peptidique normalisant le métabolisme dans les tissus osseux et cartilagineux, composition pharmaceutique à base de ladite substance et procédé d'application afférent
JPH06321774A (ja) 全身麻酔薬とセレギリンを含有する麻酔薬組成物
CA2389476C (fr) Traitement de la dyskinesie
EP0813873A1 (fr) Compositions pharmaceutiques comprenants de la mirtazapine et un ou plusieurs inhibiteurs sélectifs d'assimilation de sérotonine
Wellman et al. Effects of paraventricular hypothalamic microinjections of phenylpropanolamine and d-amphetamine on mash intake in rats
JP2021503481A (ja) μオピオイド受容体のポリマーアゴニスト

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: B1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1998940410

Country of ref document: EP

ENP Entry into the national phase in:

Ref document number: 2302167

Country of ref document: CA

Ref country code: CA

Ref document number: 2302167

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase in:

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 09486815

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1998940410

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1998940410

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载